Company Profile
Hyperfine Stock Price, News & Analysis
Company overview
Business overview
Hyperfine is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Hyperfine is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Hyperfine follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Hyperfine sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
HYPR is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Hyperfine’s catalysts are Swoop adoption, broader point-of-care imaging penetration, and any workflow or reimbursement progress that helps the device get used more often. The company needs to keep proving that portable MRI has a real commercial lane.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Hyperfine, Inc. Reports First Quarter 2026 Financial Results
Source: Hyperfine
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.